RXDX — Prometheus Biosciences Income Statement
0.000.00%
HealthcareSpeculativeLarge Cap
- $9.56bn
- $8.85bn
- $6.81m
Annual income statement for Prometheus Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1.12 | 1.23 | 3.13 | 6.81 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6.8 | 17.1 | 30.2 | 91.5 | 153 |
Operating Profit | -6.8 | -16 | -29 | -88.4 | -146 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.79 | -16.7 | -31.1 | -90.2 | -142 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.79 | -16.7 | -31.1 | -90.2 | -142 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -6.79 | -29.7 | -37.1 | -90.2 | -142 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.79 | -29.7 | -37.1 | -90.2 | -142 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.182 | -0.597 | -0.898 | -2.86 | -3.49 |
Dividends per Share |